Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 13/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 4/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6685220 | 0.98 | HSD11B1 (0.55) | HSD11B1KMT2AMEN1MAOBMAOA | |
| Ammonia Solution, Strong SCHEMBL6683995 | 0.81 | HSD11B1 (0.59) | HSD11B1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL6683445 | 0.79 | HSD11B1 (0.57) | HSD11B1KMT2AMEN1MAOBMAOA | |
| Hydrochloric Acid SCHEMBL6683835 | 0.79 | HSD11B1 (0.57) | HSD11B1KMT2AMEN1MAOBMAOA | |
| SCHEMBL6684562 | 0.78 | HSD11B1 (0.56) | HSD11B1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL6682399 | 0.77 | HSD11B1 (0.55) | HSD11B1KMT2AMEN1MAOBMAOA | |
| SCHEMBL6897706 | 0.77 | HSD11B1 (0.62) | HSD11B1KMT2AMEN1MAOBMAOA | |
| Hydrochloric Acid SCHEMBL6901794 | 0.76 | HSD11B1 (0.60) | HSD11B1KMT2AMEN1MAOBMAOA | |
| SCHEMBL7083524 | 0.73 | HSD11B1 (0.57) | HSD11B1KMT2AMEN1 | |
| SCHEMBL6680354 | 0.72 | HSD11B1 (0.78) | HSD11B1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6828318-B2 | Amines such as 2-(2-(2-phenyl)adamantyl)ethylamine, used as neurotransmitter antagonists, for prophylaxis of neurodegenerative disorders and as analgesics | VERNALIS RESEARCH LIMITED (GB) | 2004-12-07 | — | — | US | claimed |
| EP-1305306-B1 | 2-ADAMANTYLETHYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RES LTD (GB) | 2004-11-24 | — | — | EP | claimed |
| US-20030207881-A1 | 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission | VERNALIS RESEARCH LIMITED (GB) | 2003-11-06 | — | — | US | claimed |
| EP-1305306-A2 | 2-ADAMANTYLETHYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2003-05-02 | — | — | EP | claimed |
| WO-2002008219-A2 | 2-ADAMANTYLETHYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2002-01-31 | — | — | WO | claimed |
| US-6828318-B2 | Amines such as 2-(2-(2-phenyl)adamantyl)ethylamine, used as neurotransmitter antagonists, for prophylaxis of neurodegenerative disorders and as analgesics | VERNALIS RESEARCH LIMITED (GB) | 2004-12-07 | — | — | US | disclosed |
| EP-1305306-B1 | 2-ADAMANTYLETHYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RES LTD (GB) | 2004-11-24 | — | — | EP | disclosed |
| US-20030207881-A1 | 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission | VERNALIS RESEARCH LIMITED (GB) | 2003-11-06 | — | — | US | disclosed |
| EP-1305306-A2 | 2-ADAMANTYLETHYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002008219-A2 | 2-ADAMANTYLETHYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207881-A1 | 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission | SLC1A2, SLC18A2, GRM2 | HSD11B1 1563/4885KMT2A 1213/4885MEN1 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.